EHC 2025 at a glance
Explore EHC 2025 with LucidQuest. Our preview highlights key updates in headache and migraine science, clinical controversies, new therapies, and emerging AI tools, helping you plan your schedule and focus on the sessions that matter most.
📅 Build your schedule around the topics that interest you. 📥 Download the EHC 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From EHC 2025 Scientific Presentations
CGRP-Targeted Therapies
-
Durable, rapid CGRP-mAbs and gepants deliver 68–85% ≥50% responses.
-
Eptinezumab shows 10–20 minute onset in acute infusion.
Combination & Dual-Mechanism Strategies
-
mAbs + onabotulinumtoxinA or mAbs + gepants yield additive 3–7 monthly migraine day (MMD) reductions.
-
Supported by NorMig phase III and pragmatic real-world cohorts.
Long-Term Durability & Differentiation
-
HERCULES reports 85% sustained responses.
-
Fremanezumab leads long-term success; atogepant shows favorable cognition, tolerability, and ≥50% response.
Non-Pharmacologic & Physical Therapies
-
Laser acupuncture, tDCS, sTMS reduce days and disability.
-
GONB achieves ≥50% relief in 75% with low adverse events.
Pharmacologic Preventive (Non-CGRP)
-
Thiamine, fluoxetine, venlafaxine modestly reduce frequency.
-
Flunarizine shows earlier headache-day reduction and tolerability advantages vs valproate or topiramate.
Acute Treatments & Cluster/TACs
-
Almotriptan, naratriptan effective for acute treatment.
-
Steroids, aminophylline aid PDPH.
-
Galcanezumab and nVNS show strongest TAC prevention evidence.
Artificial Intelligence and Machine Learning at EHC 2025
AI-Augmented Clinical Decision-Making
Systems predict CGRP-mAb response with 69.7% sensitivity and improve training performance (OSCE +22.5).
Precision ML for Treatment Stratification:
-
REFINE and SkåNeuro predictors—including baseline EHF category (r = 0.63) and menstrual patterns—guide individualized selection.
mHealth & Wearable Forecasting:
-
BioCer shows AUC 0.51–0.59; personalization and multimodal inputs needed for short-term attack prediction.
AI Imaging & IIH Triage
-
Meta-analyses support image-first workflows with pooled sensitivity 0.77 and AUC 0.84; specificity remains limited.
📅 Build your schedule around the topics that interest you.
📥 Download the EHC 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.